MedTrace Logo

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

NCT00025636 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplant may allow the doctors to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which combination chemotherapy regimen given before peripheral stem cell transplant is more effective in treating relapsed Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy followed by peripheral stem cell transplant to see how well they work in treating patients with relapsed Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

carmustine

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

dexamethasone

DRUG

etoposide

DRUG

melphalan

DRUG

methotrexate

DRUG

vincristine sulfate

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • EBMT Solid Tumors Working Party

    collaborator OTHER

  • German Hodgkin's Lymphoma Study Group

    lead OTHER

Principal Investigators

  • Andreas Engert, MD · Medizinische Universitaetsklinik I at the University of Cologne

  • J. W. Baars, MD, PhD · The Netherlands Cancer Institute

  • Norbert Schmitz, MD, PhD · Asklepios Klinik St. Georg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31

Countries

  • Belgium
  • Croatia
  • Denmark
  • Germany
  • Netherlands
  • Poland
  • Portugal
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00025636 on ClinicalTrials.gov